Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat Phase 2 in ESRD Anemia
NCT02260193Phase 2Completed
- Sponsor
- Akebia Therapeutics
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Akebia Therapeutics. Primary endpoints: Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average at Week 8, Change From Pre-dose Average in Hgb Level to The End-of-study Average at Week 16 and 1 more. Started Sep 2014; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02260193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260193.